News Chart CervoMed Inc.

Equities

CRVO

US15713L1098

Delayed Nasdaq Other stock markets 12:15:41 2024-06-20 pm EDT			5-day change	1st Jan Change
20.32 ^USD	+4.58%		+2.23%	+164.74%

Jun. 11	CervoMed Inc. Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies	CI
May. 29	JonesTrading Starts CervoMed With Buy Rating, $70 Price Target	MT

b5a05bbb4d64d8552b4344b.FsqEL_CgeTxCFrViBrm8uYJTGmQO9xTUIfN6RfD6VHM.eZntVr6SNWYKVIQLYt7e8rU9K11MjWGSQ6E1D5SQHQZ7s8pkhMoAegBsgQ~9b07b1d49f9ac68ed6205c1fd3276f57